ENDRA regains Nasdaq stockholders' equity compliance, faces one-year panel monitor
ENDRA Life Sciences received a Nasdaq notice on July 8, 2026 that it has regained compliance with the $2,500,000 minimum stockholders' equity requirement, after the Staff flagged a shortfall in its 2025 annual report. The company will be under a Discretionary Panel Monitor for one year from July 1, 2026, and if it falls out of compliance again within that period, it could face delisting without a cure period.
- Nasdaq Staff letter dated April 20, 2026 cited stockholders' equity below the $2,500,000 minimum, based on the 2025 Form 10-K
- Company requested a Nasdaq Hearing Panel hearing on April 27, 2026; hearing held May 28, 2026
- On July 8, 2026 Nasdaq notified the company it regained compliance
- One-year Discretionary Panel Monitor runs from July 1, 2026; a new deficiency could lead to a Delist Determination Letter and possible delisting